Bioverativ (NASDAQ:BIVV) Earns Daily Coverage Optimism Rating of 0.12

News articles about Bioverativ (NASDAQ:BIVV) have trended somewhat positive recently, Accern Sentiment reports. The research firm ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Bioverativ earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 45.5291370741141 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

These are some of the media headlines that may have effected Accern Sentiment’s scoring:

Shares of Bioverativ (NASDAQ:BIVV) traded up $1.04 during midday trading on Friday, hitting $63.75. 1,557,662 shares of the stock were exchanged, compared to its average volume of 945,665. Bioverativ has a twelve month low of $40.00 and a twelve month high of $64.68.

Bioverativ (NASDAQ:BIVV) last released its quarterly earnings results on Thursday, October 26th. The biotechnology company reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.55 by $0.25. Bioverativ had a net margin of 40.44% and a return on equity of 69.03%. The firm had revenue of $291.60 million for the quarter, compared to analysts’ expectations of $285.45 million. The company’s quarterly revenue was up 27.2% compared to the same quarter last year. research analysts forecast that Bioverativ will post 2.55 earnings per share for the current fiscal year.

A number of research analysts have recently commented on the stock. Piper Jaffray Companies restated an “overweight” rating and issued a $71.00 price target on shares of Bioverativ in a report on Monday, October 23rd. Zacks Investment Research upgraded shares of Bioverativ from a “hold” rating to a “strong-buy” rating and set a $69.00 target price on the stock in a report on Thursday, October 19th. Morgan Stanley reissued an “underweight” rating and set a $47.00 price target (up from $45.00) on shares of Bioverativ in a research report on Friday, October 6th. Argus raised shares of Bioverativ from a “hold” rating to a “buy” rating and set a $64.00 price target for the company in a research report on Wednesday, September 20th. Finally, Deutsche Bank set a $53.00 price target on shares of Bioverativ and gave the company a “hold” rating in a research report on Monday, November 20th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Bioverativ has a consensus rating of “Hold” and a consensus target price of $60.47.

COPYRIGHT VIOLATION NOTICE: This piece was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/14/bioverativ-bivv-given-media-sentiment-score-of-0-12.html.

About Bioverativ

Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.

Insider Buying and Selling by Quarter for Bioverativ (NASDAQ:BIVV)

Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply